ABUS 10-Q: SEC filing

Arbutus Biopharma Corporation

Filed with the SEC on Nov 10, 2026 · accession 0001447028-26-000064

ABUS filed a 10-Q (quarterly report) with the SEC on Nov 10, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +1.7% by the first close after the filing.

Summary of the filing

Arbutus Biopharma Corporation filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and recent corporate developments.

For details, click here →How to read a 10-Q →

Key details

FilerArbutus Biopharma Corporation

How ABUS stock reacted

Close before

$3.72

Nov 9, 2026

First close after

+1.75%

$3.79

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ABUS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ABUS?

Click here

Frequently asked questions

What did ABUS file with the SEC on Nov 10, 2026?

ABUS filed a 10-Q (SEC filing). Arbutus Biopharma Corporation filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and recent corporate developments.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

How did ABUS stock react to this filing?

ABUS closed at $3.72 before the filing and $3.79 on Nov 10, 2026 (+1.75%).

Other ABUS SEC filings

Get alerts when ABUS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

ABUS overview ABUS analysis ABUS news Latest SEC filings